An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis
- First Online:
- 163 Downloads
To determine whether a regimen of cyclosporine (CSA) and methotrexate (MTX), or CSA and hydroxychloroquine (HCQ) introduced in early rheumatoid arthritis (RA) can produce a significant improvement in clinical outcome and/or retard radiographic damage in comparison with standard monotherapy with CSA alone.
One hundred five patients with active RA of less than 36 months duration, who had never previously been treated with immunosuppressive agents, were included in a 12-month, multi-center, open, randomized trial. Patients who fulfilled the criteria for early severe RA were randomized to receive either combination therapy (CSA+MTX n=34, CSA+HCQ n=35) or CSA alone (n=36).
CSA+MTX was more effective than the other two treatment groups in controlling RA symptoms. CSA+MTX did not show a significant radiographic progression according to Larsen–Dale (0.90±3.89 compared to baseline values, P>0.05); moreover, patients treated with CSA alone or CSA+HCQ showed a significant worsening of Larsen–Dale score (2.91±5.99 and 2.97±4.28 respectively vs baseline values, P<0.05), although not significant when compared with the CSA+HCQ group (P=0.56 and 0.39, respectively).
This trial indicated that CSA+MTX was more effective than the other two treatments in improving clinical data and inhibiting radiographic progression, although the differences were not significant in this relatively small study. However, the difference was significant in favor of CSA+MTX regarding ACR 50% response.
KeywordsRheumatoid arthritis Cyclosporine A Methotrexate Hydroxychloroquine
- 6.Devlin J, Gough A, Huisson A, Perkins P, Holder R, Reece R Arthur V, Emery P (1997) The acute phase and function in early rheumatoid arthritis: C-reactive protein levels correlate with functional outcome. J Rheumatol 24:9–13Google Scholar
- 9.Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, Wakefield RJ, Reece RJ, Miles S, Adebaio A, Gough A, Helliwell P, Martin M, Huston G, Pease C, Veale DJ, Isaacs J, van der Heide DM, Emery P (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809–1819CrossRefPubMedGoogle Scholar
- 10.Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318PubMedGoogle Scholar
- 13.Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939PubMedGoogle Scholar
- 14.Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I (2000) Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of lefluonomide in patients with rheumatoid arthritis. Lefluonomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 43:495–505CrossRefPubMedGoogle Scholar
- 20.Dawes PT, Tunn E, Fowler PD (1987) Combined gold and hydroxychloroquine in rheumatoid arthritis. Br J Rheumatol (suppl 1) 26:11–14Google Scholar
- 21.Cronstein BN (1996) Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 16:662–666Google Scholar
- 22.Landewé RBM, Miltenburg AMM, Breedveld FC, Daha MR, Dijkmans BAC (1992) cyclosporine and chloroquine synergistically inhibit the interferon-γ production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 19:1353–1357PubMedGoogle Scholar
- 23.Salmeron G, Lipsky PE (1983) Immunosuppressive potential of antimalarials. Am J Med 75:19–24Google Scholar
- 24.Mackenzie AH, Scherbel AL (1980) Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 6:545–566Google Scholar
- 25.Ferraccioli GF, Bambara LM, Ferraris M, Perpigneno G, Cattaneo R, Porzio F, Accardo S, Mattara L, Zoppini A, Benucci M, Ostumi PA, Pasero G (1997) Effects of cyclosporin on joint damage in rheumatoid arthritis. Clin Exp Rheumatol 15 [Suppl 17] 83–89Google Scholar
- 26.Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magarò M, Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della Casa-Alberighi O (1996) Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 37:1006–1015Google Scholar
- 29.Kushner I, Dawson NV (1992) Changing perspectives in the treatment of rheumatoid arthritis. J Rheumatol19:1831–1834Google Scholar
- 33.Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481–491Google Scholar
- 34.Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, Canesi B, Fumagalli M, Mastaglio C, Mathieu A (1993) The Italian version of the functional disability index of the health assessment questionnaire. A reliable instrument for multicenter studies in rheumatoid arthritis. Clin Exp Rheumatol 11:123–128PubMedGoogle Scholar
- 35.Fries JF, Spitz PW, Young DY (1992) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9: 789–793Google Scholar
- 36.Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American college of Rheumatology Association 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35: 498-502Google Scholar
- 39.Larsen A (1999) How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 10:1974–1975Google Scholar
- 40.Stuart AA (1955) A test for homogeneity of the marginal distributions in a two-way classification. Biometrica 42: 412–416Google Scholar
- 41.Paulus HE, Egger MJ, Ward JR, Williams HJ (1990) Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 33: 477–484PubMedGoogle Scholar
- 45.Farr M, Bacon PA (1995) How and when should combination therapy be used? The role of anchor drug. Br J Rheumatol [Suppl 2] 34:100–103Google Scholar
- 46.Panayi GS, Tugwell P (1994) The use of cyclosporin A in rheumatoid arthritis: conclusion of an international review. Br J Rheumatol 33 [Suppl 3] 967–969Google Scholar
- 47.Tugwell O, Baker P (1995) Guidelines for the use of cyclosporine in rheumatoid arthritis. Clin Rheumatol 14 [Suppl 2] 37–41Google Scholar